Indications

Precision Therapy for Solid Cancers: Particularly indicated for unresectable advanced/metastatic liver cancer (e.g., TACE as the standard therapy), metastatic liver cancer (e.g., colorectal cancer liver metastasis), and applicable to lung cancer, renal cell carcinoma, uterine fibroids, osteosarcoma, etc. It effectively controls cancer progression, alleviates symptoms (e.g., hemostasis for lung cancer-related hemoptysis), or creates surgical conditions (e.g., reducing tumor volume).

Preferred Option for Systemically Intolerant Patients: Offers a low-invasive treatment alternative for the elderly, or patients with compromised liver function, or individuals unable to tolerate radiotherapy/ chemotherapy.

Advantages

Minimally Invasive and Precise: Requires only a needle-sized puncture site, with microcatheters delivering therapy directly to cancer microvasculature, avoiding damage to normal tissues. Fast postoperative recovery (usually ambulatory within 24 hours).

Enhanced Eficacy: Local drug concentration can reach 20-100 times that of systemic chemotherapy. Embolic agents significantly increase cancer necrosis rate after blood supply interruption (e.g., drug-eluting bead TACE enables sustained drug release for 7-14 days), while reducing systemic toxic efects (e.g., hair loss and myelosuppression incidence reduced by >60%).

Flexible Combination Therapy: Can synergize with targeted agents (e.g., lenvatinib) and immunotherapy (e.g., PD-1 antibodies) to form a comprehensive "local embolization + systemic anti-cancer" protocol, overcoming resistance limitations of single-modality therapy. Supports repeated treatments to adapt to dynamic cancer changes.